Miracor is an Austrian medical device company dedicated to develop and commercialize the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) technology. Miracor was founded in May 2008 by Professor Werner Mohl and the European venture capital firms Earlybird and Delta Partners. Prof. Mohl has published more than 15 scientific articles in this field over the last 25 years.
The PICSO® technology intermittently occludes the outflow of venous blood from the heart muscle. This occlusion shortly increases the pressure in the myocardium which is believed to have a positive effect after a heart attack. Clinical data is available documenting the positive impact of PICSO® in patients undergoing revascularization procedures after thrombolytic therapy and in stable angina patients.
Miracor has developed a completely new platform for the PICSO® technology called the Miracor PICSO® Impulse System consisting of a driving console and associated catheters. The company is conducting new post-market clinical trials to document the safety and effectiveness of the PICSO® Impulse System in acute coronary patients undergoing coronary revascularization with percutaneous coronary intervention (PCI-stenting).
Our team consists of weathered medical device professionals who has developed and launched innovative and advanced medical devices world-wide.